Health Canada's Foreign Reliance Order: A Faster Drug-Approval Pathway and How to Qualify

Health Canada has proposed a new way to approve some drugs faster. The Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs, widely called the Ministerial Reliance Order (MRO), would let the Minister of Health accept parts of a review already completed by a trusted foreign regulator, rather than repeating that same work in Canada. For eligible products, this could shorten the path to a Canadian Notice of Compliance. This article explains what the Order does, who can use it, the practical catches, and how to prepare a submission that qualifies.

Executive summary

• What it is: A Ministerial Order under section 30.06 of the Food and Drugs Act that lets Health Canada deem certain parts of a drug review complete based on a foreign regulator's decision or documents.
• Status: Pre-published in the Canada Gazette, Part I on 20 December 2025. The comment period opened for 70 days and was extended to 14 March 2026. Publication in the Canada Gazette, Part II is expected in summer 2026, and the Order would come into force on that date.
• Who it covers: Certain classes of new human and veterinary drugs, set out on a list incorporated by reference (the IbR List). That list is not yet published and is expected to start small, with lower-risk products first.
• Three pathways: General Deeming, 120-Day Filing, and Joint Reviews.
• The catch: The Order does not waive any requirement. A full submission is still required, and Health Canada always reviews the parts specific to Canada, such as the product monograph, brand name, labelling, and risk management plan.
• Bottom line: Faster access is possible, but only for well-prepared dossiers that map the foreign file to Canadian requirements and justify every difference.

Why this matters now

To sell a new drug in Canada, a manufacturer files a submission and Health Canada examines its safety, efficacy, and quality before issuing a Notice of Compliance. These reviews are thorough, and they take time. Industry has raised concerns for years that products reach Canadian patients later than they reach patients in larger markets, partly because Canada is a smaller share of the global market and partly because full reviews are resource intensive.

The Foreign Reliance Order is Health Canada's response to part of that problem. It is one piece of the Government of Canada's broader Red Tape Review, launched in July 2025 to cut duplication and align Canadian rules with those of comparable regulators. The idea behind reliance is simple: if a drug has already been reviewed carefully by a regulator whose standards align with Canada's, Health Canada can focus its own effort on what is unique to Canada instead of re-examining the entire file.

For pharmaceutical, biologic, and radiopharmaceutical companies, that is a meaningful shift. It creates a potential fast lane, but it also creates a new discipline: your Canadian submission has to be built so that the foreign work can actually be relied upon. That is where preparation, and expert regulatory support, make the difference.

What is Health Canada's Foreign Reliance Order?

Quick answer: The Foreign Reliance Order is a Ministerial Order that allows Health Canada to treat certain parts of a drug review as complete based on a decision or documents from a trusted foreign regulatory authority, instead of conducting its own full examination of those parts.

The legal engine is section 30.06 of the Food and Drugs Act. That provision lets the Minister of Health, by order, deem that specified requirements of the Act or its regulations are met for a defined class of products, based on a decision of, or a document or information produced by, a foreign regulatory authority. The Minister can only make such an order where it serves a health or safety purpose or the public interest, and where it is unlikely to create unacceptable risks or uncertainties.

The Order works by targeting one specific requirement in the Food and Drug Regulations: section C.08.004, which requires the Minister to complete an examination of a new drug submission before authorizing it. Where the Order's conditions are met, that examination requirement is deemed to have been satisfied for the parts the manufacturer identifies, on the basis of the foreign regulator's work.

What does deeming mean in plain terms?

Deeming does not mean Health Canada automatically approves a foreign drug. It means that, for the specific parts of the submission a manufacturer asks to have deemed, Health Canada does not repeat the substantive scientific review that a listed foreign regulator has already done. Health Canada still confirms that all conditions of the Order are met, still reviews everything specific to Canada, and still issues or declines the Notice of Compliance. The manufacturer chooses which parts to put forward for deeming from three categories:

• Chemistry and manufacturing (C&M) information
• Non-clinical (pre-clinical) information
• Clinical information

What is the IbR List?

The Order only applies to drugs that fall within a class set out on the List of Classes of Drugs and Foreign Regulatory Authorities for the Purposes of Reliance on Decisions or Documents, incorporated by reference into the Order and referred to as the IbR List. The list does two things: it names the eligible drug classes, and it names which foreign regulators can be relied on for each class. It is designed to be updated over time as Health Canada gains experience.

Importantly, when the Order was pre-published, the IbR List did not yet name specific drug classes or specific regulators. Health Canada has signalled that the list will start with a limited set of lower-risk products and expand later. If your product's class or your foreign regulator is not on the list, the Order does not apply, no matter how strong the foreign approval is.

Why the Foreign Reliance Order matters for your business

Quick answer: For eligible products, the Order can reduce duplicate review effort, cut the number of information requests, and support earlier availability in Canada. For products that are not eligible, nothing changes.

Health Canada's own cost-benefit analysis expects a modest but real efficiency gain, estimating fewer clarification requests during review (about 1.5 fewer per submission that uses deeming) and a net benefit measured in the millions of dollars over ten years. The Department expects only about 19 submissions per year to use deeming at the start, which reflects how narrow the initial IbR List is likely to be.

The strategic point for leadership is this: reliance rewards companies that already operate in multiple jurisdictions and keep disciplined, well-organized dossiers. If you have a positive decision from a regulator that Health Canada trusts, and your Canadian and foreign products are closely matched, you may reach the Canadian market with less duplicated review. If your file is disorganized or your Canadian product differs from the foreign one in ways you cannot cleanly justify, the pathway will not help and may even slow you down.

The three reliance pathways

Quick answer: The Order sets out three self-contained scenarios in which Health Canada can deem part of its examination complete: General Deeming, 120-Day Filing, and Joint Reviews. Each has its own eligible submission types and its own evidence requirements.

General Deeming

This is the most familiar scenario. A foreign regulator on the IbR List has already authorized the drug, and the manufacturer asks Health Canada to deem one or more parts of its examination (C&M, non-clinical, or clinical) complete based on that decision. The flexibility to deem a single component is useful: a company might have Health Canada deem the C&M review while Canada looks more closely at clinical differences.

120-Day Filing

This scenario is built for speed. A manufacturer can file in Canada within 120 days of filing the same application with a listed foreign regulator, before that regulator has made its decision. This lets Health Canada begin work on the parts of the file that are not being deemed, so an authorization can follow soon after the foreign decision is granted. The trade-off is that all three components must be deemed together, and this option applies to non-comparative submissions. Once the foreign regulator authorizes the drug, the manufacturer must confirm the decision and update Health Canada on any differences that emerged.

Joint Reviews

Here, Health Canada reviews the drug at the same time as one or more foreign regulators, sharing the work. The Order lets Health Canada deem the components covered by the partner's review report, so it can more fully leverage a review it participated in. This builds on established international work-sharing, including the Access Consortium, a group of regulators (Australia's TGA, Singapore's HSA, Switzerland's Swissmedic, the United Kingdom's MHRA, and Health Canada) that already conducts joint reviews.

Which drugs and regulators qualify?

Quick answer: A drug qualifies only if its class and a matching foreign regulator appear on the IbR List, and if the Canadian product matches the foreign product on medicinal ingredient, strength, dosage form, and route of administration, with conditions of use that fall within those approved abroad.

The core matching rule is strict. The drug you propose for Canada must have the same medicinal ingredient, strength, dosage form, and route of administration as the foreign drug, and its conditions of use must fall within the foreign conditions of use. The Order does allow certain differences (for example, different packaging, product markings, or a colourant added to comply with Canadian rules), but only if you describe every difference and demonstrate it will not affect the drug's safety or effectiveness. If a difference could affect safety or effectiveness, that component will not be deemed and Health Canada will review it in full.

When Health Canada decides which regulators to add to the IbR List, it considers several factors: how closely the regulator's standards and requirements align with Canada's, the regulator's history of collaboration with Health Canada, and whether the regulator conducts thorough reviews. The regulators Health Canada already works with closely, such as the U.S. FDA, the European Medicines Agency (EMA), and its Access Consortium partners (Australia's TGA, the United Kingdom's MHRA, Switzerland's Swissmedic, and Singapore's HSA), are natural candidates. Even so, the confirmed list of eligible regulators will be published separately, and companies should not assume any particular regulator is included until the IbR List is final.

Which products are likely first?

Health Canada has indicated it will begin with lower-risk classes. Examples it has flagged as candidates for the initial list include drugs with pediatric conditions of use not currently authorized in Canada, child-friendly formulations, drugs for companion (non food-producing) animals not authorized in Canada, and drugs for food-producing animals where there is an unmet need. This signals a deliberately cautious rollout, with broader classes expected to follow.

What is not eligible

The Order does not extend to extraordinary use new drug submissions or their supplements, and it does not apply to emergency or alternate pathways such as the Special Access Program, Emergency Drug Release for veterinary drugs, or public health emergency drugs. Reliance orders under section 30.06 also cannot be made for cosmetics.

What stays the same: the catch behind the fast lane

Quick answer: The Order does not exempt you from any requirement of the Food and Drug Regulations. You still file a complete submission, you still meet all post-market obligations, and Health Canada always reviews the parts of the file that are specific to Canada.

This is the most misunderstood point, and the one where submissions go wrong. Reliance is not a shortcut around the dossier. The manufacturer must file a full submission in the normal way, plus additional evidence proving the Order's conditions are met. Health Canada always examines the Canada-specific elements listed below, and these are never deemed.

A few further points matter for planning:

• Post-market obligations continue. After a Notice of Compliance is issued, all normal Canadian post-market requirements apply. You must also describe any post-market measures the foreign regulator imposed (such as confirmatory trials), show which are relevant in Canada, and notify Health Canada as those measures are fulfilled.
• Intellectual property is unchanged. Data protection, protection under the Patented Medicines (Notice of Compliance) Regulations, and Certificate of Supplementary Protection remain available exactly as they would without the Order.
• The foreign decision cannot itself be a reliance decision. For General Deeming and 120-Day Filing, the foreign authorization you rely on must not have been based on that regulator's own reliance on another regulator, with a narrow exception for joint reviews among listed regulators.
• Prior refusals can disqualify you. If a related Canadian submission was previously refused, or was withdrawn after a notice of deficiency or non-compliance, deeming may not be available.

How to qualify: preparing a reliance submission step by step

Quick answer: Confirm eligibility against the IbR List, match your Canadian product to the foreign one, choose the right pathway, build the full Canadian dossier, and document and justify every difference. The work is front-loaded and detail-driven.

Below is a practical sequence based on how experienced regulatory teams approach a reliance-based file.

1. Run an eligibility assessment first. Confirm that your drug's class and your foreign regulator will appear on the IbR List (Part 1 for General Deeming and 120-Day Filing, Part 2 for joint reviews). If they are not listed, consider a standard pathway.
2. Match the products. Verify the same medicinal ingredient, strength, dosage form, and route of administration, and confirm that Canadian conditions of use fall within the foreign conditions.
3. Choose the pathway and the components. Decide between General Deeming, 120-Day Filing, and Joint Review, and identify which components (C&M, non-clinical, clinical) you will ask to have deemed.
4. Build the complete Canadian submission. Nothing under the Food and Drug Regulations is waived. The submission must be complete and correctly structured in the Common Technical Document format.
5. Assemble the reliance evidence. Gather proof of the foreign authorization, the foreign-approved labels, and the underlying review information you must possess or be able to access.
6. Document and justify every difference. List each difference between the Canadian and foreign product for the components being deemed, and demonstrate that none affects safety or effectiveness.
7. Disclose withdrawals and refusals. If a related foreign application in the same class was withdrawn or refused, disclose it and explain why the reasons would not affect the Canadian product.
8. Map post-market measures. Identify foreign post-market measures, translate them to Canadian equivalents, and plan how you will implement and report on them.
9. Prepare Canada-specific components in parallel. Product monograph, brand name, labelling, risk management plan, look-alike or sound-alike assessment, and any withdrawal periods still need full, Canada-ready work.

Compliance checklist

Use this as a pre-submission readiness check:

• Drug class and a matching regulator confirmed on the IbR List
• Product match confirmed: medicinal ingredient, strength, dosage form, route of administration
• Canadian conditions of use fall within the foreign conditions of use
• Pathway selected and components to deem identified
• Complete Canadian dossier assembled in Common Technical Document format
• Foreign authorization evidence and foreign-approved labels included
• Every difference documented and justified as not affecting safety or effectiveness
• Any foreign withdrawals or refusals disclosed with rationale
• Foreign post-market measures mapped to Canadian equivalents
• Canada-specific components prepared: product monograph, brand name, labelling, risk management plan
• Confirmed the foreign decision was not itself a reliance decision (unless a listed joint review)

Common mistakes to avoid

Even strong companies stumble on reliance files. These are the errors that most often cause delays or lost eligibility:

• Treating a foreign approval as automatic in Canada. It is not. Deeming still requires a complete file and full conditions met.
• Assuming a lighter submission. The dossier is not smaller. In some ways it is larger, because you add reliance evidence and difference justifications on top of the standard file.
• Under-documenting differences. Vague statements that differences are minor will not pass. Each difference needs a clear, evidence-based rationale.
• Neglecting Canada-specific components. Weak product monographs, unresolved brand-name issues, or an incomplete risk management plan will hold up an otherwise deemable submission.
• Filing when the class or regulator is not listed. If the IbR List does not cover you, the Order does not apply.
• Relying on a foreign reliance decision. If the foreign authorization was itself based on reliance, it generally cannot be used.
• Missing the 120-day window. The early-filing option is time-bound and unforgiving.
• Overlooking post-market and notification duties. Foreign-measure notifications and standard Canadian post-market obligations both continue after approval.
• Poor dossier mapping. A file that does not clearly align the foreign work to Canadian requirements invites information requests and delay.
• Ignoring downstream timelines. Faster Health Canada authorization does not automatically speed pricing and reimbursement steps, which should be planned in parallel.

Timeline and what happens next

Quick answer: The Order was pre-published on 20 December 2025, the comment period closed on 14 March 2026, and Health Canada expects publication in the Canada Gazette, Part II in summer 2026. Implementation guidance and the confirmed IbR List will follow.

Companies should treat the coming months as preparation time. The Order text tells you the structure, but the details that decide whether you can use it, the eligible classes, the listed regulators, and the operational guidance, will arrive with and after Part II. Building your eligibility analysis and dossier strategy now means you can move quickly when the list is published.

It is also worth watching related moves on Health Canada's Forward Regulatory Plan. A similar ministerial class order for certain medical devices authorized by other regulators is proposed, and a separate Ministerial Order for low-risk non-prescription drugs follows the same faster-path logic. If your organization also tracks the shift to Agile Licensing and terms and conditions for drugs, the same themes of international alignment and lifecycle oversight run through all of them.

How MFLRC can help

Quick answer: MFLRC helps pharmaceutical, biologic, and radiopharmaceutical companies decide whether the reliance pathway fits, then build submissions that qualify, from eligibility assessment through dossier bridging and Canada-specific components.

Reliance rewards preparation, and preparation is exactly what we do. With more than 20 years of Quality Assurance and Regulatory Affairs experience across pharmaceuticals, biologics, food, and cannabis, MFLRC provides senior-led, practical guidance rather than generic checklists. We can support you across the full lifecycle:

• Reliance-pathway eligibility assessment. We evaluate whether your product's class and your foreign regulator are likely to fit the IbR List, and which pathway best suits your situation. This is part of our regulatory affairs, licensing, and import and export support.
• Submission strategy and dossier bridging. We map your foreign dossier to Canadian requirements, structure the Common Technical Document, and build the difference justifications that make or break a deemed submission. See our pharmaceuticals regulatory support.
• Quality systems and documentation. Strong C&M files and quality documentation are central to reliance. Our quality assurance services cover quality management systems, SOPs, records, and stability planning.
• Gap assessments and audit readiness. We identify weaknesses before Health Canada does, through our audit services, including gap analyses and mock inspections.
• Validation support. Where C&M differences or manufacturing changes are involved, our pharmaceutical validation services help you demonstrate control.

Whether you are entering Canada for the first time or expanding an existing portfolio, we help you turn a trusted foreign approval into a well-prepared Canadian submission. Explore our full range of regulated markets and services, or book a consultation to discuss your product.

Frequently asked questions

What is Health Canada's Foreign Reliance Order?

It is a Ministerial Order under section 30.06 of the Food and Drugs Act, often called the Ministerial Reliance Order, that lets Health Canada deem certain parts of a drug review complete based on a decision or documents from a trusted foreign regulator, instead of repeating that review in Canada.

Is the Order in force yet?

Not yet. It was pre-published in the Canada Gazette, Part I on 20 December 2025, and the comment period closed on 14 March 2026. Health Canada expects to publish it in the Canada Gazette, Part II in summer 2026, and it would come into force on that publication date.

Which foreign regulators will qualify?

Health Canada has not yet published the confirmed list. Eligible regulators will appear on the IbR List, chosen based on how closely their standards align with Canada's, their history of collaboration, and the quality of their reviews. Regulators such as the FDA, the EMA, and Access Consortium partners (TGA, MHRA, Swissmedic, and HSA) are natural candidates, but nothing is confirmed until the list is final.

Does reliance mean Health Canada will not review my drug at all?

No. Health Canada still confirms that all conditions are met, always reviews the parts of the file specific to Canada such as the product monograph, brand name, labelling, and risk management plan, and issues or declines the Notice of Compliance. Only the specific components you ask to have deemed skip a repeat substantive review.

What is the difference between General Deeming, 120-Day Filing, and Joint Review?

General Deeming applies when the foreign regulator has already authorized the drug, and you can deem one or more components. 120-Day Filing lets you file in Canada within 120 days of the foreign application, before the foreign decision, deeming all three components together. Joint Review applies when Health Canada reviews the drug jointly with one or more listed regulators and deems the components covered by the partner's report.

Which drugs are eligible first?

Health Canada plans to start with lower-risk classes. Early candidates include drugs with pediatric uses not yet authorized in Canada, child-friendly formulations, and certain veterinary products where there is an unmet need. Broader classes are expected to be added over time.

Does the Order change data protection or patent rights?

No. Data protection, protection under the Patented Medicines (Notice of Compliance) Regulations, and Certificate of Supplementary Protection remain available exactly as they would without the Order.

How should my company prepare now?

Start with an eligibility assessment, confirm your Canadian and foreign products match, choose the right pathway, and build a complete dossier with strong difference justifications and Canada-ready components. Preparing now means you can move quickly once the IbR List and guidance are published. MFLRC can help you get submission-ready.

Conclusion

The Foreign Reliance Order is one of the most significant changes to Canadian drug review in years. It signals that Health Canada is willing to lean on trusted international partners to bring products to patients sooner. For companies that are organized, multi-jurisdictional, and disciplined about documentation, it opens a genuine fast lane. For everyone else, it is a reminder that the quality of your dossier decides your speed to market.

The opportunity is real, but it favours the prepared. The IbR List, the eligible regulators, and the operational guidance are still to come, which makes the next several months the right time to assess your options and get your submissions ready.

Need help deciding whether the reliance pathway fits your product, or preparing a submission that qualifies? Contact MFLRC for senior regulatory guidance tailored to your business.

Sources and references

• Canada Gazette, Part I: the proposed Order (pre-published 20 December 2025).
• Health Canada: additional information notice for the Ministerial Reliance Order.
• Health Canada: 2026 to 2028 Forward Regulatory Plan.
• Health Canada: Decision of foreign regulatory authority guide.
• Food and Drugs Act, section 30.06 (Justice Laws Website).
• Government of Canada: Report on Red Tape Reduction.
• U.S. Food and Drug Administration.
• European Medicines Agency.